JP2022553041A5 - - Google Patents
Info
- Publication number
- JP2022553041A5 JP2022553041A5 JP2022523453A JP2022523453A JP2022553041A5 JP 2022553041 A5 JP2022553041 A5 JP 2022553041A5 JP 2022523453 A JP2022523453 A JP 2022523453A JP 2022523453 A JP2022523453 A JP 2022523453A JP 2022553041 A5 JP2022553041 A5 JP 2022553041A5
- Authority
- JP
- Japan
- Prior art keywords
- subject
- months
- combination
- administered
- trastuzumab
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962923659P | 2019-10-21 | 2019-10-21 | |
| US62/923,659 | 2019-10-21 | ||
| PCT/US2020/056489 WO2021080983A1 (en) | 2019-10-21 | 2020-10-20 | Methods of treating her2 positive breast cancer with tucatinib in combination with capecitabine and trastuzumab |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022553041A JP2022553041A (ja) | 2022-12-21 |
| JP2022553041A5 true JP2022553041A5 (enExample) | 2023-10-13 |
Family
ID=73598175
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022523453A Pending JP2022553041A (ja) | 2019-10-21 | 2020-10-20 | Ｈｅｒ２陽性乳がんをカペシタビンおよびトラスツズマブと併用してツカチニブで治療する方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240092936A1 (enExample) |
| EP (1) | EP4048275A1 (enExample) |
| JP (1) | JP2022553041A (enExample) |
| KR (1) | KR20220086627A (enExample) |
| CN (1) | CN114746094A (enExample) |
| AU (1) | AU2020370058A1 (enExample) |
| CA (1) | CA3156820A1 (enExample) |
| IL (1) | IL292332A (enExample) |
| MX (1) | MX2022004699A (enExample) |
| WO (1) | WO2021080983A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112019022280A2 (pt) | 2017-04-28 | 2020-05-19 | Seattle Genetics Inc | tratamento de cânceres de her2 positivo |
| CN115252793A (zh) * | 2022-08-15 | 2022-11-01 | 新疆医科大学第三附属医院 | 一种乳腺癌靶向抑制因子及其在乳腺癌治疗中的用途 |
| CN116473923B (zh) * | 2023-05-29 | 2024-05-14 | 杭州剂泰医药科技有限责任公司 | 一种奈拉替尼固体分散体组合物及其制备方法和应用 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US4957735A (en) | 1984-06-12 | 1990-09-18 | The University Of Tennessee Research Corporation | Target-sensitive immunoliposomes- preparation and characterization |
| US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
| US4902505A (en) | 1986-07-30 | 1990-02-20 | Alkermes | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5004697A (en) | 1987-08-17 | 1991-04-02 | Univ. Of Ca | Cationized antibodies for delivery through the blood-brain barrier |
| US5055303A (en) | 1989-01-31 | 1991-10-08 | Kv Pharmaceutical Company | Solid controlled release bioadherent emulsions |
| US5271961A (en) | 1989-11-06 | 1993-12-21 | Alkermes Controlled Therapeutics, Inc. | Method for producing protein microspheres |
| US5188837A (en) | 1989-11-13 | 1993-02-23 | Nova Pharmaceutical Corporation | Lipsopheres for controlled delivery of substances |
| US5268164A (en) | 1990-04-23 | 1993-12-07 | Alkermes, Inc. | Increasing blood-brain barrier permeability with permeabilizer peptides |
| US5254342A (en) | 1991-09-30 | 1993-10-19 | University Of Southern California | Compositions and methods for enhanced transepithelial and transendothelial transport or active agents |
| DE69311538D1 (de) | 1992-03-12 | 1997-07-17 | Alkermes Inc | Acth enthaltende mikrokugeln mit gesteuerter abgabe |
| US5534496A (en) | 1992-07-07 | 1996-07-09 | University Of Southern California | Methods and compositions to enhance epithelial drug transport |
| US5514670A (en) | 1993-08-13 | 1996-05-07 | Pharmos Corporation | Submicron emulsions for delivery of peptides |
| AU2012323890A1 (en) | 2011-10-14 | 2014-05-29 | Array Biopharma Inc. | Polymorphs of arry-380, a selective ErbB2 inhibitor and pharmaceutical compositions containing them |
| WO2013056108A2 (en) | 2011-10-14 | 2013-04-18 | Array Biopharma Inc. | Solid dispersion |
| BR112019022280A2 (pt) * | 2017-04-28 | 2020-05-19 | Seattle Genetics Inc | tratamento de cânceres de her2 positivo |
| EP4058024A1 (en) * | 2019-11-15 | 2022-09-21 | Seagen Inc. | Methods of treating her2 positive breast cancer with tucatinib in combination with an anti-her2 antibody-drug conjugate |
| MX2022011160A (es) * | 2020-03-11 | 2022-10-18 | Seagen Inc | Metodos de tratar canceres mutantes de her2 con tucatinib. |
-
2020
- 2020-10-20 AU AU2020370058A patent/AU2020370058A1/en active Pending
- 2020-10-20 US US17/768,290 patent/US20240092936A1/en not_active Abandoned
- 2020-10-20 CN CN202080077966.9A patent/CN114746094A/zh active Pending
- 2020-10-20 CA CA3156820A patent/CA3156820A1/en active Pending
- 2020-10-20 JP JP2022523453A patent/JP2022553041A/ja active Pending
- 2020-10-20 WO PCT/US2020/056489 patent/WO2021080983A1/en not_active Ceased
- 2020-10-20 EP EP20812457.8A patent/EP4048275A1/en not_active Withdrawn
- 2020-10-20 IL IL292332A patent/IL292332A/en unknown
- 2020-10-20 KR KR1020227016776A patent/KR20220086627A/ko not_active Ceased
- 2020-10-20 MX MX2022004699A patent/MX2022004699A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023502929A5 (enExample) | ||
| JP2022553041A5 (enExample) | ||
| RU2011125518A (ru) | Антиангиогенная терапия, применяемая для лечения рака молочной железы | |
| JP2017031160A5 (enExample) | ||
| JP2012509889A5 (enExample) | ||
| JP2020517696A5 (enExample) | ||
| JP2025509510A5 (enExample) | ||
| JP2021523233A5 (enExample) | ||
| EP1684770B1 (en) | Oligo-beta-(1,3)-glucan and monoclonal antibodies against cancer | |
| JP2024520901A5 (enExample) | ||
| IL292332A (en) | Methods of treating her2 positive breast cancer with tucatinib in combination with capecitabine and trastuzumab | |
| JP2023500888A5 (enExample) | ||
| JP2023500697A5 (enExample) | ||
| JP2023527794A5 (enExample) | ||
| Wijesundara et al. | Plasmapheresis for extrapontine myelinolysis: a case series and a literature review | |
| JP2023510854A5 (enExample) | ||
| DE69519924T2 (de) | Gammaglobuline enthaltende immunotherapeutische präparate für die behandlung von krebskrankheiten | |
| JP2024540044A5 (enExample) | ||
| JP2024521105A5 (enExample) | ||
| JP2022547061A5 (enExample) | ||
| Car et al. | A double-blind multicentre comparison of diclofenac sodium and naproxen in osteoarthrosis of the hip | |
| JP2025526402A5 (enExample) | ||
| RU2678103C2 (ru) | Противоопухолевое средство, содержащее противоопухолевый комплекс платины, и усилитель противоопухолевого эффекта | |
| JP2024503379A5 (enExample) | ||
| EP3770172A1 (en) | Anti-vegfr-2 antibody |